Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division.
PFE
· Healthcare · Drug Manufacturers - General
· Market cap $157.5B
QuantHub Original Research · Updated 2026-09-18
·
Medium QualityB-tier business, B-tier valuation with 12.0% upside to $30.94 fair value.Fair Value
PFE is trading near fair value. No urgent action needed.
QuantHub Research: Investment Thesis
Maturing Phase
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating margin of 25.1% show genuine pricing power in the product portfolio, but TTM net margin of only 6.8% and ROE of 4.9% reveal how much of that gross profit is consumed by research, litigation, impairments, and interest on $60.495 billion of long-term debt plus $2.699 billion of current debt. Revenue grew 2.6% year over year in the most recent quarter, while earnings fell 108.5% year over year in the most recent quarter, a swing driven by the prior-year COVID revenue base and by a $3.8 billion impairment tied to unfavorable Phase 3 sigvotatug vedotin results. At $27.64, the shares trade at 2.47 times sales, 36.33 times trailing earnings, 14.34 times free cash flow, and 17.41 times EV/EBITDA, a mixed multiple set that reflects depressed trailing earnings rather than a cheap core franchise. The blended fair value estimate of $30.94 implies 12.0% upside, and the analyst consensus of Hold with a $30 average target implies 8.6% upside, so the stock is modestly undervalued versus blended fair value while sitting in a fair regime relative to its own five-year history. The central question is whether the growth portfolio and cost programs can outrun roughly $1.1 billion of 2026 exclusivity erosion, Medicare Maximum Fair Price pressure on Eliquis, and the 2027 negotiated prices for Ibrance and Xtandi.
Pfizer screens as modestly undervalued rather than outright cheap. The 36.33 trailing P/E looks expensive, but it is distorted by a 108.5% year-over-year earnings decline in the most recent quarter and a $3.8 billion impairment, so trailing earnings understate normalized earning power. On cash flow the picture is more reasonable: 14.34 times free cash flow and 17.41 times EV/EBITDA are undemanding for a large-cap pharmaceutical with 71.3% TTM gross margin. The market is pricing three things: skepticism that the growth portfolio can offset roughly $1.1 billion of 2026 exclusivity erosion and accelerating erosion through 2030, uncertainty over Medicare Maximum Fair Price on Eliquis and 2027 negotiated prices for Ibrance and Xtandi, and balance-sheet caution given $60.495 billion of long-term debt. The valuation regime is fair versus five-year history, and the blended fair value of $30.94 implies 12.0% upside, so the shares are undervalued versus blended fair value even though they are not statistically cheap on trailing earnings. Analyst consensus of Hold with a $30 average target, only 8.6% above the current price, shows the sell side sees limited near-term re-rating potential without clearer evidence on 2026 guidance delivery and cost savings.
12–18 Month Outlook
Over the next 18 months Pfizer faces a genuine tug-of-war. The bull path requires delivering revenue within the raised $60.5 billion to $62.5 billion guidance range and adjusted EPS of $2.80 to $3.00 while absorbing roughly $4 billion of assumed COVID-product revenue and approximately $1.1 billion of exclusivity erosion, and demonstrating early execution against the $1.0 billion cost-base and $1.5 billion manufacturing-optimization savings programs. If those land, the 14.34 times P/FCF multiple and 12.0% upside to $30.94 fair value could compress toward the $30 analyst target and possibly beyond. The bear path is that Eliquis Medicare Maximum Fair Price, 2027 negotiated prices for Ibrance and Xtandi, and accelerating exclusivity losses through 2030 keep revenue growth near the 2.6% year-over-year pace seen in the most recent quarter while the 108.5% year-over-year earnings decline and 6.8% TTM net margin persist, leaving the stock range-bound around the current $27.64 with the $60.495 billion debt load limiting buyback support. The most likely outcome is a modest re-rating toward fair value rather than a dramatic move in either direction, which is consistent with the Hold consensus and the 8.6% upside to the average target.
Bull vs Bear
Bull Case
The blended fair value estimate of $30.94 implies 12.0% upside from $27.64, and the analyst average target of $30 implies 8.6% upside, giving a positive expected return even under a Hold consensus.
Free cash flow of $1.93 per share against a $27.64 price produces a 14.34 times P/FCF multiple, a reasonable cash-flow valuation for a business with 71.3% TTM gross margin and 25.1% TTM operating margin.
Revenue grew 2.6% year over year in the most recent quarter, showing the non-COVID base is expanding even as reported earnings absorb impairments and prior-year COVID comparisons.
Pfizer has raised full-year 2026 revenue guidance to a $60.5 billion to $62.5 billion range with adjusted EPS of $2.80 to $3.00, and management is pursuing an additional $1.0 billion of cost-base savings plus $1.5 billion of manufacturing-optimization savings.
Management remains firmly committed to maintaining the dividend, and the growth portfolio is performing well, which supports income-oriented holders through the exclusivity transition.
Bear Case
Earnings fell 108.5% year over year in the most recent quarter, and TTM net margin of just 6.8% with ROE of 4.9% shows how little of the 71.3% gross margin reaches the bottom line.
Pfizer forecasts approximately $1.1 billion of 2026 revenue erosion from exclusivity expirations, with management expecting the pace to accelerate through 2030, a structural headwind to the revenue base.
Eliquis Medicare Maximum Fair Price took effect on January 1, 2026, and negotiated prices for Ibrance and Xtandi are scheduled for 2027, raising the risk of lower realized prices and margin compression on major franchises.
Unfavorable Phase 3 sigvotatug vedotin results triggered a $3.8 billion impairment, demonstrating that late-stage clinical setbacks can force write-downs and reduce expected future growth.
At June 28, 2026, Pfizer carried $60.495 billion of long-term debt and $2.699 billion of current debt, which constrains buybacks and raises the importance of sustained cash-flow generation and deleveraging.
Leadership & Competitive Position
Albert Bourla
Tenure7 yrs
Beats guidance75% of qtrs
Capital allocationFair
Albert Bourla has led Pfizer since 2019, overseeing the COVID-19 vaccine and antiviral franchise that generated extraordinary revenue and cash flow, and subsequently directing capital into large-scale acquisitions and pipeline expansion. The current record is mixed: the growth portfolio is performing well and management is committed to the dividend, but a $3.8 billion impairment on sigvotatug vedotin, a 108.5% year-over-year earnings decline in the most recent quarter, and $60.495 billion of long-term debt show that capital deployment has not yet translated into durable earnings growth. Management has raised full-year 2026 revenue guidance to $60.5 billion to $62.5 billion and is executing an additional $1.0 billion cost-base savings program plus $1.5 billion of manufacturing-optimization savings, which are the key tests of capital discipline.
Competitive Moat
narrowing
intangible assetsbrand
Pfizer holds leading positions in cardiovascular care through Eliquis, in pneumococcal and meningococcal vaccines through the Prevnar family, in COVID-19 vaccines and oral antivirals through Comirnaty and Paxlovid, and in rare disease through Vyndaqel. These franchises face exclusivity expirations that management expects to erode approximately $1.1 billion of 2026 revenue and to accelerate through 2030, and Medicare Maximum Fair Price on Eliquis plus 2027 negotiated prices for Ibrance and Xtandi directly pressure realized pricing on major products.
Competitors: Merck & Co. (MRK), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Johnson & Johnson (JNJ), AstraZeneca (AZN)
Disruption: Medium. Generic and biosimilar entries accelerate revenue erosion after patent expiry, and competition in oncology, vaccines, cardiometabolic disease, and specialty medicines limits market share and pricing power, though Pfizer's breadth across therapeutic areas and its vaccine and antiviral franchises provide some insulation.
QuantHub Research
Valuation
Multiple
Current
Median 3yr
Median 5yr
Min 5yr
Max 5yr
P/E
36.33x
18.68x
18.31x
9.16x
76.67x
P/S
2.47x
2.36x
2.73x
2.26x
4.07x
P/FCF
14.34x
15.59x
15.28x
11.04x
33.9x
P/S 2.47x vs 5yr range 2.26-4.07x (P25=2.26x, median=2.73x, P75=2.86x)
Price Outlook (5-Year)
Bear
$25
-2.9%/yr
Base
$31
1.5%/yr
fair value
Bull
$37
5.3%/yr
Bear/Base/Bull anchored to QuantHub fair value estimate. Base = headline fair value; Bear −20%; Bull +20%.
Pfizer forecasts approximately $1.1 billion of 2026 revenue erosion from exclusivity expirations, and management expects the pace to accelerate through 2030, which pressures the revenue base and the growth portfolio's ability to offset declines.
Regulatory and pricing pressure
high
Eliquis Medicare Maximum Fair Price took effect on January 1, 2026, while negotiated prices for Ibrance and Xtandi are scheduled for 2027, increasing the risk of lower realized prices and margin compression on major franchises.
Pipeline and clinical execution
high
Unfavorable Phase 3 sigvotatug vedotin results triggered a $3.8 billion impairment, illustrating the risk that late-stage clinical setbacks reduce expected future growth and require further write-downs.
Earnings deterioration
high
Earnings fell 108.5% year over year in the most recent quarter, and TTM net margin of 6.8% with ROE of 4.9% shows limited bottom-line conversion despite a 71.3% TTM gross margin.
Competitive threats
medium
Competition in oncology, vaccines, cardiometabolic disease, and specialty medicines can limit market share and pricing power, while generic and biosimilar entries can accelerate revenue erosion after patent expiry.
Leverage and financial flexibility
medium
At June 28, 2026, Pfizer had $60.495 billion of long-term debt and $2.699 billion of current debt, which constrains buybacks and raises the importance of sustained cash-flow generation and deleveraging.
Litigation and product liability
medium
Pfizer faces ongoing patent, product-liability, and related legal risks that can create financial costs, operational distraction, and uncertainty around the timing and severity of competitive entry.
Dividend sustainability questions
medium
Recent coverage questions whether the dividend can be sustained, and while management remains firmly committed to maintaining it, the combination of a 108.5% year-over-year earnings decline in the most recent quarter and $60.495 billion of long-term debt keeps the payout under scrutiny.
Growth Engines
Non-COVID portfolio expansionmature
The base business grew 2.6% year over year in the most recent quarter, with growth products in oncology, vaccines, and specialty care offsetting declining COVID revenue, which management assumes at approximately $4 billion for full-year 2026.
Cost savings and manufacturing optimizationearly
Management is targeting an additional $1.0 billion of cost-base savings and $1.5 billion of manufacturing-optimization savings, which would flow directly to operating margin if delivered on schedule.
Rare disease and specialty franchisesmature
Vyndaqel, BeneFIX, and related rare disease therapies serve smaller patient populations with high unmet need and durable pricing, though they face their own eventual exclusivity timelines.
Biosimilars and contract manufacturingmature
Inflectra, Xeljanz, and Retacrit plus the contract manufacturing division provide lower-margin but steadier revenue streams that diversify away from patented small-molecule risk.
Pfizer's Dividend Faces Big Questions. Here Are 3 Reasons It Should Survive.
Coverage acknowledges pressure on the dividend but argues management remains firmly committed to maintaining it and that the growth portfolio is performing well, supporting the income case through the exclusivity transition.
2026-09-17
How Much Do You Really Need Invested to Replace a $130,000 Salary With Dividends?
A general dividend-income piece that highlights the trade-off between chasing yield and exposure to leverage, dividend cuts, and NAV erosion, a relevant framing for Pfizer given its $60.495 billion long-term debt load.
This is AI-powered fundamental analysis built from scratch — not aggregated analyst ratings. Get this research for your entire portfolio plus daily briefings, research signals, and options income.
QuantHub research is focused on quality businesses with durable competitive advantages — companies we'd want to own for 3–5 years or more. We are not short-term traders. Every analysis is built around a single question: is this a great business available at a reasonable price for a long-term investor?
We start where most analysts finish: the fundamentals. For every company, our AI ingests years of financial statements — revenue, margins, free cash flow, and how the business has been valued by the market across multiple cycles. But numbers alone don't tell you whether a business is worth owning.
The harder work is qualitative. We assess the competitive moat: is it widening or eroding? We read the leadership track record — how capital has been allocated, whether management has earned trust through consistent execution. We look at what the market is afraid of, and whether that fear is priced in fairly or irrationally.
Valuation is always relative. A stock is cheap or expensive compared to its own history. We build scenario matrices anchored to 5-year historical multiples, then ask: what has to go right for the upside case, and what's the floor if it doesn't?
Finally, we write an 18-month forward outlook — not a price target, but a mental model of where this business will be and what the narrative will look like. Every note is dated and versioned. When material facts change, we update the thesis.
Frequently Asked Questions
Is PFE undervalued?
PFE is currently fairly valued at $28.67 vs. our fair value estimate of $30.94 (+8% upside).
What is PFE's fair value?
QuantHub Research estimates PFE's fair value at $30.94 based on our proprietary valuation model incorporating historical P/S, P/E, and P/FCF multiples over a 5-year range.
What are the key risks for PFE?
Loss of exclusivity: Pfizer forecasts approximately $1.1 billion of 2026 revenue erosion from exclusivity expirations, and management expects the pace to accelerate through 2030, which pressures the revenue base and the growth portfolio's ability to offset declines. Regulatory and pricing pressure: Eliquis Medicare Maximum Fair Price took effect on January 1, 2026, while negotiated prices for Ibrance and Xtandi are scheduled for 2027, increasing the risk of lower realized prices and margin compression on major franchises. Pipeline and clinical execution: Unfavorable Phase 3 sigvotatug vedotin results triggered a $3.8 billion impairment, illustrating the risk that late-stage clinical setbacks reduce expected future growth and require further write-downs.
What is the bull case for PFE?
The blended fair value estimate of $30.94 implies 12.0% upside from $27.64, and the analyst average target of $30 implies 8.6% upside, giving a positive expected return even under a Hold consensus. Free cash flow of $1.93 per share against a $27.64 price produces a 14.34 times P/FCF multiple, a reasonable cash-flow valuation for a business with 71.3% TTM gross margin and 25.1% TTM operating margin. Revenue grew 2.6% year over year in the most recent quarter, showing the non-COVID base is expandi
How confident is QuantHub in PFE?
QuantHub has moderate conviction in PFE. Research last updated 2026-09-18.